Rheumatoid arthratis

Document Sample
Rheumatoid arthratis Powered By Docstoc
					Rhuematoid Arthritis                                                                 Abstract




Chapter – 1                                   ABSTARCT

BACKGROUND: PPAR agonists are used for the management of the Rheumatoid Arthritis
where classical DMARDs therapy is inresponsive. Telmisartan is a partial PPAR  agonist which is
having a different binding site with receptor than full agonist so it might affect the effect the
full ppar  agonist.



OBJECTIVE: Our main aim was to study the modulatory effect of telmisartan on anti
inflammatory effect PPAR  full agonist in Complete Freund’s Adjuvant Induced Arthritis Model
in Rats. Here we take rosiglitazone as a full ppar  agonist.




Materials and Methods: Arthritis was induced in Wistar rats by a single sub plantar injection
(0.2 ml) of Complete Freund’s Adjuvant (C.F.A.) containing heat killed Mycobacterium
tuberculosis (0.2 mg) into the left footpad. Rats were treated with either rosiglitazone (3mg/kg,
p.o.) alone or in combination with telmisartan (5mg/kg, p.o) from day 0 to 12. The animals
were maintained for up to 21st day to allow development of secondary lesions. The effects of
drugs were evaluated by change in paw volume, body weight and arthritis index, change in
erythrocyte sedimentation rate (ESR), detection of serum rheumatoid factor (RF), serum tumor
necrosis factor-α (TNF-α) and by histopathology of knee joint.




Result




Rushikesh Kansara                      M.Pharm. Thesis 08-09                               page-
Rhuematoid Arthritis                           Abstract


Conclusion




Rushikesh Kansara      M.Pharm. Thesis 08-09       page-

				
DOCUMENT INFO
Categories:
Stats:
views:13
posted:10/6/2011
language:English
pages:2
Description: PPAR agonists are used for the management of the Rheumatoid Arthritis where classical DMARDs therapy is inresponsive. Telmisartan is a partial PPAR g agonist which is having a different binding site with receptor than full agonist so it might affect the effect the full ppar g agonist.